OneWorld Health named business leader in public health on '2004 Scientific American 50'

11/03/04

Honor comes as CEO Victoria Hale presents positive preliminary results in final stage of clinical trial

San Francisco, Calif. Nov. 8, 2004 The Institute for OneWorld Health has been selected by the Board of Editors at Scientific American magazine as the Business Leader in Public Health and Epidemiology for creating the first nonprofit U.S. drug firm that seeks to develop new, affordable medicines for people in the developing world. In recognition, OneWorld Health will be included in the Scientific American 50, the magazine's prestigious annual list recognizing outstanding acts of leadership in science and technology from the past year.

"We are very honored to be named as a Business Leader of the Scientific American 50," stated Victoria Hale, Ph.D., founder and CEO of OneWorld Health. "Through the unique business model of a nonprofit pharmaceutical company, we are able to target diseases of the poorest people in the world, where the development of new medicines is clearly not profitable. By creating collaborative partnerships among industry, academia, foundations, and the nonprofit sectors, we are addressing some of the world's most devastating diseases. As a result, we can develop new medicines and save lives of people most in need."

The 2004 Scientific American 50 will appear in Scientific American's December issue, available at newsstands on Nov. 23. Editor-In-Chief John Rennie described his magazine's commitment saying, "Scientific American believes strongly that the best hope for a safer, healthier, more prosperous world rests in the enlightened use of technology. The Scientific American 50 is our annual opportunity to salute the people and organizations making that possible through their outstanding efforts as leaders of research, industry and policymaking."

Proving the viability of OneWorld Health's business model, Dr. Hale announced today preliminary positive results of a Phase III clinical trial in India for a low-cost drug to cure a deadly parasitic disease, visceral leishmaniasis (VL) during a scientific session at the 53rd annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) in Miami, Fla. VL kills approximately 200,000 people each year, mostly in the Indian subcontinent. Treatments today are expensive, toxic, or ineffective.

OneWorld Health expects to lower the cost per cure to about US$10 per adult treatment compared with current therapies which cost up to US$200. Regulatory approval will be sought in India in 2005.

Source: Eurekalert & others

Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
    Published on PsychCentral.com. All rights reserved.

 

 

It is never too late to give up your prejudices.
-- Henry David Thoreau